Molecular insight in cancer treatment and prevention

被引：8

作者：

Balducci, Lodovico ^{[1
]}

机构：

[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA

来源：

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY | 2007年 / 39卷 / 7-8期

关键词：

cancer; molecular insights; treatment; prevention; targeted therapy;

D O I：

10.1016/j.biocel.2007.03.005

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 [生物化学与分子生物学]; 081704 [应用化学];

摘要：

This article explores the impact of new insights in the biology of cancer on the treatment and the prevention of this disease. There are two types of targeted cancer treatment, afforded by the molecular profile of cancer. One concerns the use of agents targeted on a specific component of the cancer cells (e.g., CD20 in lymphoma) or on a specific survival function of the cancer cell (growth-factor-receptor interaction; transduction cascade). The other concerns the recognition of tumors that are more or less likely to benefit from cytotoxic chemotherapy according to their genomic or proteomic profile. Cancer prevention may benefit from new molecular insight in cancer biology as these processes allow early diagnosis of cancer, identification of patients at risk for cancer, and may provide intermediate markers for chemoprevention studies. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：1329 / 1336

页数：8

共 62 条

[1]

Review of capecitabine as oral treatment of gastric, gastroesophageal, and Esophageal cancers [J].

Ajani, Jaffer .

CANCER, 2006, 107 (02) :221-231

[2]

More than structural cells, fibroblasts create and orchestrate the tumor microenvironment [J].

Baglole, Carolyn J. ;

Ray, Denise M. ;

Bernstein, Steven H. ;

Feldon, Steven E. ;

Smith, Terry J. ;

Sime, Patricia J. ;

Phipps, Richard P. .

IMMUNOLOGICAL INVESTIGATIONS, 2006, 35 (3-4) :297-325

[3]

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group [J].

Bedikian, Agop Y. ;

Millward, Michael ;

Pehamberger, Hubert ;

Conry, Robert ;

Gore, Martin ;

Trefzer, Uwe ;

Pavlick, Anna C. ;

DeConti, Ronald ;

Hersh, Evan M. ;

Hersey, Peter ;

Kirkwood, John M. ;

Haluska, Frank G. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4738-4745

[4]

Gene promoter methylation in plasma and sputum increases with lung cancer risk [J].

Belinsky, SA ;

Klinge, DM ;

Dekker, JD ;

Smith, MW ;

Bocklage, TJ ;

Gilliland, FD ;

Crowell, RE ;

Karp, DD ;

Stidley, CA ;

Picchi, MA .

CLINICAL CANCER RESEARCH, 2005, 11 (18) :6505-6511

[5]

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].

Bonner, JA ;

Harari, PM ;

Giralt, J ;

Azarnia, N ;

Shin, DM ;

Cohen, RB ;

Jones, CU ;

Sur, R ;

Raben, D ;

Jassem, J ;

Ove, R ;

Kies, MS ;

Baselga, J ;

Youssoufian, H ;

Amellal, N ;

Rowinsky, EK ;

Ang, KK .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578

[6]

Genetic testing for inherited colon cancer [J].

Burt, R ;

Neklason, DW .

GASTROENTEROLOGY, 2005, 128 (06) :1696-1716

[7]

Proteasome inhibitor bortezomib for the treatment of multiple myeloma [J].

Cavo, M. .

LEUKEMIA, 2006, 20 (08) :1341-1352

[8]

Standard treatment of advanced-stage diffuse large B-cell lymphoma [J].

Coiffier, Bertrand .

SEMINARS IN HEMATOLOGY, 2006, 43 (04) :213-220

[9]

de Visser KE, 2006, CONTRIB MICROBIOL, V13, P118, DOI 10.1159/000092969

[10]

The role of alemtuzumab in the management of T-cell malignancies [J].

Dearden, Claire .

SEMINARS IN ONCOLOGY, 2006, 33 (02) :S44-S52

← 1 2 3 4 5 6 7 →